1. Volume 164, Issue 6, Pages 1956-1960 (December 2000)
USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND α1- PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCER 
PATRIK FINNE, WAN-MING ZHANG, ANSSI AUVINEN, JARI LEINONEN, LIISA MÄÄTTÄNEN, SAKARI RANNIKKO, TEUVO L.J. TAMMELA, ULF-HÅKAN STENMAN 
The Journal of Urology 
Volume 164, Issue 6, Pages (December 2000)
DOI: /S (05)
Copyright © 2000 American Urological Association, Inc. Terms and Conditions

2. Fig. 1
Correlation between uncorrected PSA-α1-protease inhibitor (API) and nonspecific background in 42 female sera without PSA immunoreactivity. PSA-α1-protease inhibitor and nonspecific background were determined in separate wells (y = − x, r = 0.91).
The Journal of Urology  , DOI: ( /S (05) )
Copyright © 2000 American Urological Association, Inc. Terms and Conditions

3. Fig. 2
Proportion of PSA-α1-protease inhibitor (API) plotted against proportion of free PSA in sera with total PSA 4 to 10 μg./l. from 44 prostate cancer cases and 210 controls. There was no correlation between proportions of PSA-α1-protease inhibitor and free PSA (r = 0.03, p = 0.56).
The Journal of Urology  , DOI: ( /S (05) )
Copyright © 2000 American Urological Association, Inc. Terms and Conditions

4. Fig. 3
ROC curves of total PSA, proportions of free PSA and PSA-α1-protease inhibitor (API), and probability of prostate cancer obtained by logistic regression analysis of logarithm of PSA-α1-protease inhibitor and proportion of free PSA in serum with PSA 4 to 10 μg./l. AUC, area under ROC curve.
The Journal of Urology  , DOI: ( /S (05) )
Copyright © 2000 American Urological Association, Inc. Terms and Conditions